CUP-Syndrom
Reference13 articles.
1. Boeckel GR, Pouyiourou M, Claßen L et al.: Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)Diagnostic and treatment of cancer of unknown primary site (CUP syndrome). Best Pract Onkol (2020) https://doi.org/10.1007/s11654-020-00207-6 2. Culine S, Lortholary A, Voigt JJ et al.: Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol (2003) https://doi.org/10.1200/JCO.2003.12.104. 3. Fizazi K, Greco FA, Pavlidis N et al.: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2015) https://doi.org/10.1093/annonc/mdv305. 4. Fizazi K, Maillard A, Penel N et al.: A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol (2019) https://doi.org/10.1093/annonc/mdz394. 5. Hayashi H, Kurata T, Takiguchi Y et al.: Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol (2019) https://doi.org/10.1200/JCO.18.00771.
|
|